Showing 1–12 of 201 resultsSorted by latest
Pharma & Biotech
AbbVie’s capital allocation demonstrates discipline through the announced 5.5% dividend increase to $1.73 per share beginning February 2026.
Boston Scientific continues its leadership across multiple high-growth therapeutic areas.
Pfizer maintain a “HOLD” rating for PFE, with the upgraded TP of $26.61 for FY26.This provides an upside potential of ~6% over the CMP of $25.17. We estimated the adjusted EPS of $3.03 for FY26. We estimate a forward P/E multiple of 8.79x and EV/EBITDA of 6.7x for FY26.
Thermo Fisher reinforced its innovation leadership in Q3FY25 with multiple high impact launches across genomics, proteomics, analytical instruments, and laboratory software.
Biogen recognizes its economics through a 50% profit share with Eisai, translating into about $42.7mn of Alzheimer’s collaboration revenue in Q3FY25. Extended supply agreements into the next decade secure manufacturing continuity and support the durability of the global rollout.
Regeneron’s pipeline remains among the most differentiated in large-cap biotech, spanning immunology, oncology, haematology, rare diseases, and newer areas such as obesity and anticoagulation.
Teva’s biosimilars platform is gaining scale, with ten products now commercialized globally. In the U.S., recent launches include Simlandi (adalimumab), Selarsdi (ustekinumab), and Epysqli (eculizumab), while Europe and international markets feature assets such as Truxima and Ranivisio.
Cigna has differentiated itself by offering consumers biosimilar access at no cost, underscoring both clinical leadership and alignment with patient value. The global biosimilars market opportunity exceeds $100bn, while the U.S. market is expected to reach $22.6bn in 2025 and compound at 17.1% through 2034.
Dr. Reddy’s continues to operate with a very strong financial foundation, with a net cash position of ₹27.5bn after adjusting for restricted cash, equity investments, and lease liabilities.
Abbott’s product innovation trajectory demonstrates balanced pipeline construction with combination of iterative and transformative innovation, generating approximately $500 million in sales from recently launched products in Q3FY25 alone, contributing 100+bps to organic sales growth
Johnson & Johnson’s MedTech segment is entering a period of accelerated growth, driven by strong execution across its highest-potential categories. Cardiovascular, Robotics, and Vision. In Q3FY25, MedTech delivered 5.6% operational sales growth, marking one of its strongest quarters in recent years and reflecting broad momentum rather than isolated product outperformance.
Agilent paid $71mn in cash dividends during Q3FY25. This represented a dividend of $0.248 per common share. During the same period, the company repurchased and retired 737,474 shares of its common stock for $85mn. These repurchases were executed under the 2023 repurchase program. This represents that Agilent Technologies is committed in returning to its shareholders.